LONDON, Jan 16 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy pill hit 3,071 U.S. prescriptions in the first four days after its launch, IQVIA data shared by analysts on Friday showed, as investors closely watch to see if the firm can ram home its first-mover advantage against rival Eli Lilly LLY.N in a competitive weight-loss market.
The data reflects retail prescriptions for oral Wegovy, not those filled through the drugmaker's online NovoCare Pharmacy, so actual prescription numbers will be higher, Barclays analysts said in a note.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments